"Leuprolide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE that regulates the synthesis and release of pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE.
| Descriptor ID |
D016729
|
| MeSH Number(s) |
D06.472.699.327.740.320.400 D12.644.400.400.740.320.400 D12.644.456.460.480 D12.644.548.365.740.320.400 D12.776.631.650.405.740.320.400
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Leuprolide".
Below are MeSH descriptors whose meaning is more specific than "Leuprolide".
This graph shows the total number of publications written about "Leuprolide" by people in this website by year, and whether "Leuprolide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 0 | 1 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Leuprolide" by people in Profiles.
-
Impact of Late Dosing on Testosterone Suppression with 2 Different Leuprolide Acetate Formulations: In Situ Gel and Microsphere. An Analysis of United States Clinical Data. J Urol. 2021 02; 205(2):554-560.
-
Hirsutism in Women. Am Fam Physician. 2019 08 01; 100(3):168-175.
-
FSH suppression and tumour control in patients with prostate cancer during androgen deprivation with a GnRH agonist or antagonist. Scand J Urol. 2018 Oct - Dec; 52(5-6):349-357.
-
Selective estrogen receptor alpha agonist GTx-758 decreases testosterone with reduced side effects of androgen deprivation therapy in men with advanced prostate cancer. Eur Urol. 2015 Feb; 67(2):334-41.
-
Editorial comment. Urology. 2013 Jan; 81(1):154; author reply 154.
-
Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostate cancer. Evid Rep Technol Assess (Summ). 1999 May; (4):i-x, 1-246, I1-36, passim.